Back to School: How biopharma can reboot drug development. Access exclusive analysis here

PE catches the wave

PE Biosystems Group's acquisition of Third Wave Technologies Inc. for $331 million in stock will enable PEB, sibling Celera Genomics Group and parent company PE Corp. to enter two new markets: high volume single nucleotide polymorphism (SNP) genotyping and

Read the full 390 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE